NCT01835587View on ClinicalTrials.gov

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 25, 2013

Primary Completion Date

November 13, 2016

Study Completion Date

May 26, 2017

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
DRUG

CC-486

Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center., New York

44106

University Hospitals Cleveland Medical Center, Cleveland

77030

MD Anderson Cancer Center The University of Texas, Houston

98109-4417

Fred Hutchinson Cancer Research Center, Seattle

B15 2TH

Queen Elizabeth Hospital UHB NHS Foundation Trust, Birmingham

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01835587 - Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). | Biotech Hunter | Biotech Hunter